摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

十二甲基环六硅氧烷 | 540-97-6

中文名称
十二甲基环六硅氧烷
中文别名
环己硅氧烷;十二甲基环己硅氧烷
英文名称
dodecamethyl-cyclohexasiloxane
英文别名
Dodecamethyl-cyclohexasiloxan;cyclohexasiloxane dodecamethyl;Dodecamethylcyclohexasiloxane;2,2,4,4,6,6,8,8,10,10,12,12-dodecamethyl-1,3,5,7,9,11-hexaoxa-2,4,6,8,10,12-hexasilacyclododecane
十二甲基环六硅氧烷化学式
CAS
540-97-6
化学式
C12H36O6Si6
mdl
——
分子量
444.927
InChiKey
IUMSDRXLFWAGNT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    -3°C
  • 沸点:
    245 °C
  • 密度:
    0,959 g/cm3
  • 闪点:
    >76°C
  • 溶解度:
    可溶于氯仿(少量)、乙酸乙酯(少量)
  • LogP:
    8.87 at 23.6℃
  • 物理描述:
    Liquid
  • 颜色/状态:
    Oily liquid
  • 气味:
    Odorless
  • 蒸汽压力:
    0.0169 mm Hg at 25 °C
  • 稳定性/保质期:

    按规格使用和贮存,不会发生分解,避免与氧化物接触。

  • 粘度:
    6.62 cSt
  • 汽化热:
    Enthalpy of vaporization: 56.1 to 62.6 kJ/mol
  • 表面张力:
    19.2 mN/m at 20 °C; 18.8 mN/m at 25 °C
  • 折光率:
    Index of refraction = 1.4015 at 20 °C
  • 保留指数:
    1342;1348;1350;1351;1353;1359;1359;1339;1341;1363;1346;1351

计算性质

  • 辛醇/水分配系数(LogP):
    4.31
  • 重原子数:
    24
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    55.4
  • 氢给体数:
    0
  • 氢受体数:
    6

ADMET

毒理性
  • 毒性总结
鉴定和使用:通常包括十二甲基环己硅氧烷(D6),其一般公式为 (-Si(CH3)2O-)x,呈环状结构,其中 x 通常小于 8,更常见的是 x 为 3-7。这种配方常用于化妆品。其它用途包括电子产品、家具、保健产品、炊具和医疗设备。它还用作表面处理、油漆、漆器和清漆。人类暴露和毒性:无数据。动物研究:D6 在大鼠口服或皮肤给药(2000 mg/kg)单次剂量时并未显示出毒性。将测试物质滴入兔眼中引起了结膜炎(红眼),所有反应在 24 小时内都已清除。D6 在兔子上连续 4 小时的皮肤应用并未引起刺激、腐蚀或染色。在大鼠上,每天以 1000 或 1500 mg/kg 体重的剂量连续给药 28 天并未产生局部或全身毒性的迹象。在大鼠的生殖/发育毒性筛选试验中,高剂量动物在肝脏(仅雌性出现脂肪变性)、肺和甲状腺中显示出显微镜下的发现。高剂量组报告了精子阳性、非妊娠雌性数量的增加。在雄性中,在两个最高剂量平上,凝血酶原时间延长;然而,没有临床凝血异常的迹象。在肝脏和肾脏(两性)以及肾上腺(仅雌性)中观察到了绝对和/或相对器官重量的增加。D6 在使用 S. typhimurium TA 98、TA100、TA1535 和 TA1537 菌株的沙门氏菌反向突变试验中的致突变性进行了评估。D6 的致突变性还在使用 E. coli WP2 uvrA 菌株的大肠杆菌反向突变试验中进行了评估。D6 在沙门氏菌反向突变试验或大肠杆菌反向突变试验中,无论是否经过活化,均未表现出致突变性。
IDENTIFICATION AND USE: Typically including dodecamethylcyclohexasiloxane (D6) with a general formula of (-Si(CH3)2O-)x in a cyclic configuration, where x is generally less than 8, and more commonly x is 3-7. This formulation is commonly used in cosmetics. Other uses include electronics, furniture, health-care products, cookware, and medical devices. It is also used as surface treatments, paint, lacquers, and varnishes. HUMAN EXPOSURE AND TOXICITY: No data. ANIMAL STUDIES: D6 was not toxic in rats when given as a single dose orally, or dermally (2000 mg/kg). Eye instillation of the test substance induced conjunctival irritation (redness) in rabbits, and all reactions had cleared within 24 hours. The 4-hour dermal application of D6 did not induce irritation, corrosion, or staining in rabbits. In rats doses of 1000 or 1500 mg/kg body weight per day for 28 days did not produced signs of local or systemic toxicity. In reproductive/developmental toxicity screening tests in rats high dose animals demonstrated microscopic findings in liver (fatty change in females only), lung, and thyroid. An increase in the number of sperm-positive, non-gravid females was reported for the high dose group. In males, prothrombin time was prolonged at the 2 highest dose levels; however, there were no clinical indications of clotting abnormalities. Absolute and/or relative organ weight increases were observed in the liver and kidneys (both sexes) and in the adrenal glands (females only). Mutagenicity of D6 in the Salmonella typhimurium reverse mutation assay was evaluated using S. typhimurium strains: TA 98, TA100, TA1535, and TA1537. The mutagenicity of D6 was also evaluated in the Escherichia coli reverse mutation assay using E. coli strain WP2 uvrA. D6 was not mutagenic in the S. typhimurium reverse mutation assay or in the E. coli reverse mutation assay with or without activation.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 解毒与急救
/SRP:/ 立即急救:确保已经进行了充分的中和。如果患者停止呼吸,请开始人工呼吸,最好使用需求阀复苏器、球囊阀面罩设备或口袋面罩,按训练操作。如有必要,执行心肺复苏。立即用缓慢流动的冲洗受污染的眼睛。不要催吐。如果患者呕吐,让患者向前倾或将其置于左侧(如果可能的话,头部向下),以保持呼吸道畅通,防止吸入。保持患者安静,维持正常体温。寻求医疗救助。 /毒物A和B/
/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 解毒与急救
/SRP:/ 基本治疗:建立专利气道(如有需要,使用口咽或鼻咽气道)。如有必要,进行吸痰。观察呼吸不足的迹象,如有需要,协助通气。通过非重复呼吸面罩以10至15升/分钟的速度给予氧气。监测肺肿,如有必要,进行治疗……。监测休克,如有必要,进行治疗……。预期癫痫发作,如有必要,进行治疗……。对于眼睛污染,立即用冲洗眼睛。在运输过程中,用0.9%的生理盐(NS)持续冲洗每只眼睛……。不要使用催吐剂。对于摄入,如果患者能吞咽、有强烈的干呕反射且不流口,则用冲洗口腔,并给予5毫升/千克,最多200毫升的进行稀释……。在去污染后,用干燥的无菌敷料覆盖皮肤烧伤……。/毒药A和B/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 解毒与急救
/SRP:/ 高级治疗:对于无意识、严重肺肿或严重呼吸困难的病人,考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺肿……。对于严重的支气管痉挛,考虑给予β激动剂,如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放",最低流量/。如果出现低血容量的迹象,使用0.9%生理盐(NS)或乳酸林格氏液。对于伴有低血容量迹象的低血压,谨慎给予液体。注意液体过载的迹象……。使用地西泮劳拉西泮治疗癫痫……。使用丙美卡因化物协助眼部冲洗……。 /Poisons A and B/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 非人类毒性摘录
实验室动物:急性暴露/研究人员/研究了D6的急性经口毒性,使用6周龄、禁食的Wistar大鼠(Crl:(WI)BR品系[非近交系,SPF质量];3只雄性和3只雌性)。雄性和雌性的平均体重分别为194和147克。给每只动物经口灌胃单一剂量2000 mg/kg(2.22 mL/kg)。每天观察动物,并在终末处死时(在第15天)进行宏观检查。没有任何动物死亡,也没有观察到毒性临床迹象。此外,在宏观尸检时没有发现异常。在研究期间体重的增加被认为是正常的。急性经口LD50>2000 mg/kg。
/LABORATORY ANIMALS: Acute Exposure/ /Researchers/ studied the acute oral toxicity of D6 using the 6- week-old, fasted Wistar rats (Crl: (WI) BR strain [outbred, SPF-Quality]; 3 males and 3 females). Mean body weights for males and females were 194 and 147 g, respectively. A single oral dose of 2000 mg/kg (2.22 mL/kg) was administered, by gavage, to each animal. The animals were observed daily and macroscopic examination was performed after the terminal sacrifice (on day 15). None of the animals died and no clinical signs of toxicity were observed. Additionally, no abnormalities were noted at macroscopic postmortem examination. Body weight gain during the study was considered normal. The acute oral LD50 was >2000 mg/kg.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
研究人员评估了在体外人皮肤上应用纯净的D6(用14C标记)后的经皮吸收情况。在Teflon流动扩散池系统中,半封闭条件下应用了测试物质。人表皮取自腹部皮肤(6名捐赠者)。通过切割机将带有顶层真皮的表皮从皮肤的其他部分分离出来,并且皮肤样本被复制安装。来自3名捐赠者的皮肤样本通过了屏障完整性测试。在皮肤样本下方泵入生理受体流体。在24小时的暴露期间,来自每位6名捐赠者的皮肤样本被施以纯净的14C-环六硅氧烷(14C-D6),目标剂量为6毫克/平方厘米。在实验结束时,大部分施用的剂量位于皮肤表面(46.407%的施用剂量)或者从施用部位挥发并通过活性炭陷阱收集(40.057%的施用剂量)。实际上没有14C-D6透过皮肤并进入受体流体。从所有分析样本中回收的纯净14C-D6的百分比为89.542% +/- 4.154%,其中包括在皮肤中发现的3.075%的纯净14C-D6(平均值的标准误=0.852%的施用剂量)。另一项实验的结果表明,在24小时后清洗皮肤时,观察到皮肤中的14C-D6部分并没有透过皮肤,而是继续蒸发。因此,得出结论,在本实验条件下,D6没有被经皮吸收。
/Researchers/ evaluated the percutaneous absorption of neat D6 radiolabeled with (14)C following application to human skin in vitro. The test substance was applied under semiocclusive conditions in a Teflon flowthrough diffusion cell system. Human epidermis was prepared from abdominal skin (6 donors). The epidermis with the top layer of dermis was separated from the rest of the skin by dermatoming, and the skin samples were mounted in replicate. Skin samples from 3 donors passed the barrier integrity test. A physiological receptor fluid was pumped beneath the skin samples. Skin samples from each of the 6 donors were dosed with neat (14)C-cylohexasiloxane (14C-D6) at a target dose of 6 mg/sq cm during the 24-hour-exposure period. At the conclusion of the assay, the majority of the applied dose was located on the skin surface (46.407% of applied dose) or volatilized from the dosing site and collected in charcoal traps (40.057% of applied dose). Practically no (14)C-D6 penetrated through the skin and into the receptor fluid. The percentage of applied neat (14)C-D6 recovered from all samples that were analyzed was 89.542% +/- 4.154%, which included 3.075% of the applied neat (14)C-D6 (SE of the mean = 0.852% of the applied dose) that was found in the skin. The results of an additional experiment indicated that, after the skin was washed at 24 hours, the portion of (14)C-D6 observed in the skin did not penetrate through the skin, but continued to evaporate. Thus, it was concluded that, under the conditions of this assay, D6 was not percutaneously absorbed.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
研究人员评估了14C-D6的处置情况,使用10组Fischer 344大鼠(CDF(F-344)/CrlBR品系)。这些动物的年龄在8到10周之间,体重范围分别为雄性163到219克,雌性133到155克。一组4只雄性和4只雌性大鼠单次口服给予(14)C-D6(玉米油中,1000毫克/千克体重),使用代谢笼收集尿液、粪便和呼出的空气。给药后168小时处死动物,收集选定组织和剩余尸体并分析其放射性。还分析了呼出的挥发性物质和粪便中的母体D6浓度。另一组通过颈静脉插管的大鼠(6只雄性和6只雌性)用于在给药后15分钟以及1、6、12、18、24、48、72、96、120、144和168小时测定血液中的放射性和母体D6浓度。全身放射性自显影(WBA)用于在大鼠单次口服给药D6(玉米油中)后,对雄性和雌性大鼠体内组织分布的放射性进行定性评估。WBA组的动物在给药后1、4、24、48、96和168小时处死。在雄性和雌性中,大部分给药剂量通过粪便排出。根据回收的放射性(尿液、呼出的挥发性物质、呼出的CO2、组织和尸体),D6的吸收率为11.88%(雄性)和11.83%(雌性)的给药剂量。对于回收的大部分放射性,雄性和雌性中放射性的分布模式相似。然而,呼出的挥发性物质中放射性的平报告了相当大的变异性,这可能是由于未能收集的粪便颗粒从笼子内部逸出。作者指出,这种现象可能会因为从粪便物质到空气的分配而产生一些假高值,从而影响呼出的挥发性物质和吸收的值。呼出的挥发性物质中的所有放射性都被归因于母体D6。尿液和粪便的代谢轮廓评估表明,尿液中的所有放射性都是由极性代谢物组成,而在粪便中,大部分是母体D6,含有一小部分非极性代谢物。全身放射性自显影数据支持质量平衡数据,显示大部分给药的D6在玉米油中停留在胃肠道(GI)并 在48小时内通过粪便排出。在肝脏、脂肪组织和骨髓等器官和组织中检测到低平的放射性,表明D6有一定的吸收。血液曲线的统计分析表明,血液中存在少量代谢物,这是基于放射性和母体AUCs(AUC代谢物 = AUC放射性 - AUC母体)之间的差异。
/Researchers/ evaluated the disposition of (14)C-D6 using 10 groups of Fischer 344 rats (CDF(F-344)/ CrlBR strain). The animals were 8 to 10 weeks old and body weight ranges were 163 to 219 g (males) and 133 to 155 g (females). A single oral dose of (14)C-D6 (in corn oil, 1000 mg/kg body weight) was administered to a group of 4 males and 4 females; metabolism cages were used for the collection of urine, feces, and expired air. The animals were killed at 168 hours postdosing, and selected tissues and remaining carcasses collected and analyzed for radioactivity. Expired volatiles and feces were also analyzed for parent D6 concentration. A separate group of rats (6 males and 6 females), cannulated via jugular vein, was used to determine radioactivity and parent D6 concentration in the blood at 15 minutes and at 1, 6, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours postdosing. Wholebody autoradiography (WBA) was used for qualitative in vivo assessment of tissue distribution of radioactivity in male and female rats after single oral administration of D6 (in corn oil). Animals in the WBA groups were killed at 1, 4, 24, 48, 96, and 168 hours postdosing. In males and females, the majority of the administered dose was excreted in the feces. Based on the recovered radioactivity (urine, expired volatiles, expired CO2, tissues, and carcass), the absorption of D6 was 11.88% (males) and 11.83% (females) of the administered dose. For most of the recovered radioactivity, a similar pattern of distribution of the radioactivity was noted in males and females. However, considerable variability in the levels of radioactivity in expired volatiles was reported, which may have been due to off gassing from the fecal pellets that were not collected, as intended, but remained on the inside of the cage. The authors noted that this phenomenon could potentially produce some false high values for expired volatiles and absorption due to partitioning from the fecal matter into the air. All of the radioactivity in the expired volatiles was attributed to parent D6. Metabolic profile evaluation of the urine and feces indicated that all of the radioactivity in the urine consisted of polar metabolites, whereas, in the feces, the majority was parent D6, with a trace nonpolar metabolite. Whole body autoradiography data supported mass balance data showing that the majority of administered D6 in corn oil stayed in the gastrointestinal (GI) tract and was excreted in the feces within 48 hours. Low levels of radioactivity were detected in organs and tissues, such as the liver, fat tissue, and bone marrow, indicating some absorption of D6. Statistical analysis of blood curves indicated the presence of small amounts of metabolites in the blood, based on the difference between radioactivity and parent AUCs (AUCmetabolites = AUCradioactivity AUCparent).
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
硅胶(聚二甲基硅氧烷)凝胶用于乳房植入物时已知会通过完整的硅胶弹性体壳体迁移,导致在植入物表面出现临床上可观察到的“凝胶渗出”。尽管已经使用特定元素的分析测量了带有硅胶假体妇女的囊膜组织中的浓度,但迄今为止尚未对这些组织进行过针对硅胶的具体调查。本研究结合了特定元素的电感耦合等离子体高分辨率同位素稀释质谱(ICP-HR-IDMS)和特定物种的气相色谱耦合质谱(GC-MS),用于分析硅胶凝胶填充乳房植入物妇女(n=3)的假体囊膜、肌肉和脂肪组织中的硅氧烷,以及作为对照的未增大乳房妇女(n=3)的乳腺组织。在所有增大乳房妇女的组织中,识别出了硅氧烷,尤其是八甲基环四硅氧烷D4)、十甲基环五硅氧烷(D5)和十二甲基环六硅氧烷(D6)。根据分析的硅氧烷物种和组织类型,检测到的硅氧烷平在约10-1,400 ng/g的范围内;所有组织样本中检测到的总含量在约8,900-85,000 ng/g的范围内。在两名带有假体的患者的纤维蛋白层和脂肪组织中检测到较高的平,范围从25-90 ng/g。在对照乳腺组织样本中没有检测到硅氧烷。这项通过结合特定元素和特定物种的分析技术对人类组织的研究首次清楚地表明,硅氧烷会从假体泄漏并积聚在其周围组织中。
Silicone [poly(dimethylsiloxane)] gel used in breast implants has been known to migrate through intact silicone elastomer shells, resulting in the clinically observable "gel bleed" on the implant surface. Although silicon concentrations in capsular tissues of women with silicone prostheses have been measured with element-specific silicon analyses, no silicone-specific investigation of these tissues has been performed as yet. A combination of element-specific inductively coupled plasma high-resolution isotope dilution mass spectrometry (ICP-HR-IDMS) and species-specific gas chromatography coupled mass spectrometry (GC-MS) was used to analyze silicon, platinum, and siloxanes in prosthesis capsule, muscle, and fat tissues of women (n=3) who had silicone gel-filled breast implants and in breast tissue of non-augmented women (n=3) as controls. In all tissues of augmented women, siloxanes, in particular octamethylcyclotetrasiloxane (D4), decamethylcyclopentasiloxane (D5), and dodecamethylcyclohexasiloxane (D6) were identified. Depending on the siloxane species and type of tissue analyzed, siloxane levels in the range of about 10-1,400 ng/g were detected; total silicon was found in all tissue samples in the range of about 8,900-85,000 ng/g. Higher platinum levels ranging from 25-90 ng/g were detected in fibrin layer and fat tissue of two patients with prostheses. No siloxanes were detected in control breast tissue samples. This investigation of human tissues by a combination of element-specific and species-specific analytical techniques clearly demonstrates for the first time that platinum and siloxanes leak from prostheses and accumulate in their surrounding tissues.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
为了检验低分子量油在身体器官中的分布,将雌性CD-1小鼠分成不同的组,分别注射主要由六甲基环三硅氧烷、八甲基环四硅氧烷、十甲基环五硅氧烷、十二甲基环六硅氧烷和十四甲基环七硅氧烷组成的乳房植入物馏分,或者注射含有低分子量线型硅氧烷的聚二甲基硅氧烷油。小鼠在肩胛上区皮下注射,并在不同时间处死。测量了10个不同器官(大脑、心脏、肾脏、肝脏、肺、肠系膜淋巴结、卵巢、脾脏、骨骼肌和子宫)中个别低分子量油的平。在用环硅氧烷混合物处理并在3、6或9周处死的小鼠中,发现肠系膜淋巴结、卵巢和子宫中的环硅氧烷含量最高,但所有检查的器官都含有环硅氧烷。在一组在1年处死的小鼠中,大多数器官都含有可测量的环硅氧烷,其中肠系膜淋巴结、腹膜脂肪和卵巢中的含量最高。在所有研究的时间点,所有器官中都发现了相对于八甲基环四硅氧烷,十甲基环五硅氧烷和十二甲基环六硅氧烷的选择性保留。接受线型硅氧烷混合物的动物的器官在9、12和15周时收获……在大脑、肺和肠系膜淋巴结中发现了最高平,但所有其他器官都含有可测量的平。据我们所知,这些数据是首次证明,单次皮下注射后,油在体内广泛分布,并且可以持续一段较长时间。
To examine the distribution of low molecular weight silicones in body organs, separate groups of female CD-1 mice were injected with either breast implant distillate composed primarily of hexamethylcyclotrisiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, and tetradecamethylcycloheptasiloxane or a polydimethylsiloxane oil containing low molecular weight linear siloxanes. Mice were injected subcutaneously in the suprascapular area and killed at different times. Levels of individual low molecular weight silicones were measured in 10 different organs (brain, heart, kidney, liver, lung, mesenteric lymph nodes, ovaries, spleen, skeletal muscle, and uterus). In mice treated with the cyclosiloxane mixture and killed at 3, 6, or 9 weeks, highest levels of cyclosiloxanes were found in the mesenteric lymph nodes, ovaries, and uterus, but all organs examined contained cyclosiloxanes. In a cohort killed at 1 year, most organs contained measurable cyclosiloxanes with highest levels in mesenteric lymph nodes, abdominal fat, and ovaries. Of the individual cyclosiloxanes measured, selective retention of decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane relative to octamethylcyclotetrasiloxane was seen in all organs at all time points studied. Organs from animals receiving the linear siloxane mixture were harvested at 9, 12, and 15 weeks. ... Maximum levels in the brain, lungs, and mesenteric lymph nodes /were found/, but all other organs contained measurable levels. These data are, to the best of our knowledge, the first demonstration that after a single subcutaneous injection silicones are widely distributed throughout the body and can persist over an extended period.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
十二甲基环己硅氧烷(D6)的处置情况在给予单次口服1000毫克/千克体重的(14)C-D6玉米油后,对雄性和雌性F344大鼠进行了评估。动物(每组4只/性别)被安置在玻璃代谢笼中,以收集排泄物和呼出的挥发性物质。在给药后168小时,动物被处死,并收集选定的组织和剩余的尸体。所有样本均分析了放射性含量。粪便和呼出的挥发性物质还分析了母体D6的浓度。另一组动物通过颈静脉插管(每组6只/性别)用于在预定时间点测定血液中的放射性活性和母体D6的浓度。全身自动放射性显影(WBA)用于定性评估组织中放射性活性的体内分布。无论性别如何,大部分给予的放射性活性(>80%)都在粪便中排出。雄性和雌性的总吸收量(在尿液中回收的放射性活性,呼出的挥发性物质,呼出的CO2,组织和尸体)分别为11.88%和11.83%。两个性别显示出相似的处置模式(尿液:0.38%和0.32%;呼出的挥发性物质:11.20%和11.21%;呼出的 :0.13%和0.09%;组织:0.03%和0.04%;尸体:0.14%和0.17%分别为雄性和雌性)。呼出的挥发性物质中的全部放射性活性都被归因于母体D6。代谢轮廓评估显示,尿液中的全部放射性活性由极性代谢物组成,而在粪便中,大部分是母体D6,含有微量非极性代谢物。WBA数据还显示,大部分D6留在胃肠道中,并在48小时内随粪便排出。放射性活性在系统中的平较低,并分布到肝脏、棕色脂肪和骨髓等器官和组织。血液曲线的统计分析表明血液中存在少量代谢物(大约117微克等效D6*小时/克血液)。总之,大约12%的(14)C-D6在玉米油中给予F344大鼠单次口服给药后被吸收。
The disposition of (14)C-dodecamethylcyclohexasiloxane (D6) was evaluated in male and female F344 rats following a single oral administration of 1000 mg of (14)C-D6 in corn oil/kg of body weight. Animals (N=4/sex) were housed in glass metabolism cages for collection of excreta and expired volatiles. At 168 hr post-dose, animals were sacrificed and selected tissues and remaining carcasses were collected. All samples were analyzed for radioactivity content. Feces and expired volatiles were also analyzed for parent D6 concentration. A separate group of animals, cannulated via the jugular vein, (N=6/sex) was used to determine radioactivity and parent D6 concentration in blood at predetermined time points. Whole-body autoradiography (WBA) was used for qualitative in vivo assessment of tissue distribution of radioactivity. The majority of administered radioactivity (>80%), regardless of sex, was eliminated in the feces. Total absorption (radioactivity recovered in urine, expired volatiles, expired CO2, tissues and carcass) in males and females was 11.88% and 11.83%, respectively. Both sexes showed similar patterns of disposition (Urine: 0.38% and 0.32%; Expired volatiles: 11.20% and 11.21%; Expired CO2: 0.13% and 0.09%; Tissues: 0.03% and 0.04%; Carcass: 0.14% and 0.17% for males and females, respectively). The entire radioactivity in the expired volatiles was attributed to parent D6. Metabolic profile evaluation showed that the entire radioactivity in the urine consisted of polar metabolites, whereas in the feces the majority was parent D6 with a trace of nonpolar metabolite. The WBA data also showed that the majority of D6 remained in the GI tract and was excreted in feces within 48 hr. Low levels of radioactivity were systemically available and distributed to organs and tissues such as liver, brown fat and bone marrow. Statistical analysis of the blood curves indicated the presence of small levels of metabolites in the blood (approximately 117 ug equivalent D6*hr/g of blood). In summary, approximately 12% of (14)C-D6 delivered in corn oil appeared to be absorbed after a single oral administration to F344 rats.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • TSCA:
    Yes
  • 安全说明:
    S26,S36/37/39
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    3
  • 海关编码:
    29319090
  • 危险品运输编号:
    UN 1993C 3 / PGIII
  • RTECS号:
    GW2328550
  • 储存条件:
    储存于阴凉、干燥、通风良好的库房中,远离火种和热源,并防止阳光直射。包装需密封保存,避免与酸类及食用化学品混放。储区内应配备适当的材料以处理可能的泄漏。

SDS

SDS:1bce449500bab45d8591e3377e5e41d1
查看

模块 1. 化学
1.1 产品标识符
: DodECamethylcyclohexasiloxane
产品名称
1.2 鉴别的其他方法
2,2,4,4,6,6,8,8,10,10,12,12-DodECamethylcyclohexasiloxane
1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
仅用于研发。不作为药品、家庭或其它用途。

模块 2. 危险性概述
2.1 GHS-分类
非危险物质或混合物。
2.3 其它危害物 - 无

模块 3. 成分/组成信息
3.1 物 质
: 2,2,4,4,6,6,8,8,10,10,12,12-DodECamethylcyclohexasiloxane
别名
: C12H36O6Si6
分子式
: 444.92 g/mol
分子量


模块 4. 急救措施
4.1 必要的急救措施描述
吸入
如果吸入,请将患者移到新鲜空气处。 如呼吸停止,进行人工呼吸。
皮肤接触
用肥皂和大量的冲洗。
眼睛接触
冲洗眼睛作为预防措施。
食入
切勿给失去知觉者通过口喂任何东西。 用漱口。
4.2 主要症状和影响,急性和迟发效应
据我们所知,此化学,物理和毒性性质尚未经完整的研究。
4.3 及时的医疗处理和所需的特殊处理的说明和指示
无数据资料

模块 5. 消防措施
5.1 灭火介质
灭火方法及灭火剂
雾,抗乙醇泡沫,干粉或二氧化碳灭火。
5.2 源于此物质或混合物的特别的危害
碳氧化物, 二氧化硅
5.3 给消防员的建议
如必要的话,戴自给式呼吸器去救火。
5.4 进一步信息
无数据资料

模块 6. 泄露应急处理
6.1 作业人员防护措施、防护装备和应急处置程序
避免吸入蒸气、烟雾或气体。
6.2 环境保护措施
不要让产品进入下道。
6.3 泄漏化学品的收容、清除方法及所使用的处置材料
放入合适的封闭的容器中待处理。
6.4 参考其他部分
丢弃处理请参阅第13节。

模块 7. 操作处置与储存
7.1 安全操作的注意事项
无数据资料
7.2 安全储存的条件,包括任何不兼容性
贮存在阴凉处。 使容器保持密闭,储存在干燥通风处。
打开了的容器必须仔细重新封口并保持竖放位置以防止泄漏。
7.3 特定用途
无数据资料

模块 8. 接触控制和个体防护
8.1 容许浓度
最高容许浓度
没有已知的国家规定的暴露极限。
8.2 暴露控制
适当的技术控制
常规的工业卫生操作。
个体防护设备
眼/面保护
请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟) 检测与批准的设备防护眼部。
皮肤保护
戴手套取 手套在使用前必须受检查。
请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
身体保护
防渗透的衣服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。
呼吸系统防护
不需要对呼吸系统保护.对少量挥发请采用美国OV/AG (US)标准类型的 或欧洲ABEK (EU EN
14387)标准类型的呼吸器过滤器.
呼吸器使用经过测试并通过政府标准如NIOSH(US)或CEN(EU)的呼吸器和零件。

模块 9. 理化特性
9.1 基本的理化特性的信息
a) 外观与性状
形状: 液体
颜色: 无色
b) 气味
无数据资料
c) 气味阈值
无数据资料
d) pH值
无数据资料
e) 熔点/凝固点
熔点/凝固点: -3 °C
f) 沸点、初沸点和沸程
无数据资料
g) 闪点
无数据资料
h) 蒸发速率
无数据资料
i) 易燃性(固体,气体)
无数据资料
j) 高的/低的燃烧性或爆炸性限度 无数据资料
k) 蒸气压
无数据资料
l) 蒸汽密度
无数据资料
m) 密度/相对密度
0.959 g/cm3
n) 溶性
无数据资料
o) n-辛醇/分配系数
无数据资料
p) 自燃温度
无数据资料
q) 分解温度
无数据资料
r) 粘度
无数据资料

模块 10. 稳定性和反应活性
10.1 反应性
无数据资料
10.2 稳定性
无数据资料
10.3 危险反应
无数据资料
10.4 应避免的条件
无数据资料
10.5 不相容的物质
强氧化剂
10.6 危险的分解产物
其它分解产物 - 无数据资料

模块 11. 毒理学资料
11.1 毒理学影响的信息
急性毒性
无数据资料
皮肤刺激或腐蚀
无数据资料
眼睛刺激或腐蚀
无数据资料
呼吸道或皮肤过敏
无数据资料
生殖细胞致突变性
无数据资料
致癌性
IARC:
此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。
生殖毒性
无数据资料
特异性靶器官系统毒性(一次接触)
无数据资料
特异性靶器官系统毒性(反复接触)
无数据资料
吸入危险
无数据资料
潜在的健康影响
吸入 吸入可能有害。 可能引起呼吸道刺激。
摄入 如服入是有害的。
皮肤 通过皮肤吸收可能有害。 可能引起皮肤刺激。
眼睛 可能引起眼睛刺激。
接触后的征兆和症状
据我们所知,此化学,物理和毒性性质尚未经完整的研究。
附加说明
化学物质毒性作用登记: 无数据资料

模块 12. 生态学资料
12.1 生态毒性
无数据资料
12.2 持久性和降解性
无数据资料
12.3 潜在的生物累积性
无数据资料
12.4 土壤中的迁移性
无数据资料
12.5 PBT 和 vPvB的结果评价
无数据资料
12.6 其它不良影响
无数据资料

模块 13. 废弃处置
13.1 废物处理方法
产品
将剩余的和不可回收的溶液交给有许可证的公司处理。
受污染的容器和包装
按未用产品处置。

模块 14. 运输信息
14.1 联合国危险货物编号
欧洲陆运危规: - 国际海运危规: - 国际空运危规: -
14.2 联合国运输名称
欧洲陆运危规: 非危险货物
国际海运危规: 非危险货物
国际空运危规: 非危险货物
14.3 运输危险类别
欧洲陆运危规: - 国际海运危规: - 国际空运危规: -
14.4 包裹组
欧洲陆运危规: - 国际海运危规: - 国际空运危规: -
14.5 环境危险
欧洲陆运危规: 否 国际海运危规 国际空运危规: 否
海洋污染物(是/否): 否
14.6 对使用者的特别提醒
无数据资料


模块 15 - 法规信息
N/A


模块16 - 其他信息
N/A

制备方法与用途

用途通常是通过混合环状硅氧烷来制备油和橡胶。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    十二甲基环六硅氧烷 在 magnesium iodide 作用下, 反应 0.17h, 以90%的产率得到
    参考文献:
    名称:
    根本不是非配位的:环二甲基硅氧烷D n(D = Me 2 SiO; n = 6,7)和2族金属阳离子的配位化合物
    摘要:
    我们介绍了环二甲基硅氧烷D 6和D 7对碱土金属盐的配位化学。迄今为止,这些大环与碱土金属的配位化学是前所未有的,我们可以证明这些配体的配位比以前想象的要好。碱土金属盐与这些配体的直接反应即使具有相对强配位的碘化物阴离子也能产生稳定的络合物。少数违反直觉的配位化合物可以通过单晶X射线衍射分析来表征。合适的Born–Haber循环的量子化学计算表明,对于Mg 2+和Ca 2+,这些络合物确实是稳定的即使在GaI 3存在下,碘化物也用作阴离子,Sr 2+和Ba 2+也是如此。
    DOI:
    10.1021/acs.inorgchem.9b02519
  • 作为产物:
    描述:
    十二甲基环己硅烷环氧乙烷一氧化二氮 作用下, 以 溶剂黄146 为溶剂, 反应 20.0h, 生成 十二甲基环六硅氧烷
    参考文献:
    名称:
    Photolysis of (Me2Si)6 in argon matrices doped with high concentrations (ca. 20%) of N2O or C2H4O: formation of (Me2SiO)6
    摘要:
    Irradiation using a low pressure mercury lamp (lambda =ca. 250 nm) of argon matrices containing ca. 1% (Me2Si)(6) and ca. 20% ethylene oxide (C2H4O) or nitrous oxide (N2O) for a period of ca. 20 h leads to the formation of the cyclic compound (Me2SiO)(6). This has a 12-membered ring with alternating Si and O atoms. It is identified by comparison of its infrared spectrum with a spectrum of an authentic sample. The reaction appears to proceed by stepwise insertion of O atoms into Si-Si bonds. (C) 2001 Published by Elsevier Science B.V.
    DOI:
    10.1016/s0022-328x(01)01184-6
点击查看最新优质反应信息

文献信息

  • One-Step Synthesis of Siloxanes from the Direct Process Disilane Residue
    作者:Felix Neumeyer、Norbert Auner
    DOI:10.1002/chem.201603842
    日期:2016.11.21
    Direct Process for the chloromethylsilane synthesis produces a disilane residue (DPR) consisting of compounds MenSi2Cl6−n (n=1–6) in thousands of tons annually. Technologically, much effort is made to retransfer the disilanes into monosilanes suitable for introduction into the siloxane production chain for increase in economic value. Here, we report on a single step reaction to directly form cyclic, linear
    完善的用于甲基硅烷合成的Müller-Rochow直接工艺产生的乙硅烷残留物(DPR)由每年数千吨的化合物Me n Si 2 Cl 6− n(n = 1–6)组成。从技术上讲,已做了很多努力将乙硅烷重新转移到适合引入硅氧烷生产链中的甲硅烷中,以提高经济价值。在这里,我们报告了一步法反应,即在Et 2中用5 m HCl处理DPR后直接形成环状,线性和笼状硅氧烷 将O溶液在约120°C下放置60小时。对于Si-Si键裂解的简化和瞄准上产物选择性甲基化在骨架的品位提高到Ñ ≥4。而且,HCl / Et 2 O试剂也适合在可比较的条件下由相应的甲硅烷生产硅氧烷
  • Selective Formation of Alkoxychlorosilanes and Organotrialkoxysilane with Four Different Substituents by Intermolecular Exchange Reaction
    作者:Yuma Komata、Masashi Yoshikawa、Yasuhiro Tamura、Hiroaki Wada、Atsushi Shimojima、Kazuyuki Kuroda
    DOI:10.1002/asia.201601120
    日期:2016.11.22
    nanomaterials by stepwise reactions of Si−OR (R=alkyl) and Si−Cl groups. Intermolecular exchange of alkoxy and chloro groups between alkoxysilanes and chlorosilanes (functional group exchange reaction) provides an efficient and environmentally benign route to alkoxychlorosilanes. BiCl3 as a Lewis acid catalyst can promote the functional group exchange reactions more efficiently than conventional acid catalysts
    烷氧基硅烷在制备有机二氧化硅以及通过Si-OR(R =烷基)和Si-Cl基的逐步反应制备基于硅氧烷的纳米材料方面具有重要的科学和工业意义。烷氧基硅烷硅烷之间的烷氧基和基的分子间交换(官能团交换反应)为烷氧基硅烷提供了一种有效且对环境无害的途径。BiCl 3作为路易斯酸催化剂可以比常规酸催化剂更有效地促进官能团交换反应。对于具有较少数量的Si-CH 3基团的硅烷和对于具有较大数量的Si-CH 3基团的烷氧基硅烷,已观察到更高的反应性组。提出了反应机理并证明了烷氧基硅烷的选择性合成。这些发现还使我们能够合成具有四个不同取代基的有机三烷氧基硅烷
  • Hydrogenolysis of Polysilanes Catalyzed by Low‐Valent Nickel Complexes
    作者:Bruno Pribanic、Monica Trincado、Frederik Eiler、Matthias Vogt、Aleix Comas‐Vives、Hansjörg Grützmacher
    DOI:10.1002/anie.201907525
    日期:2020.9
    is very unselective, leading to multiple side products. Herein, we describe a new catalytic hydrogenation of oligo‐ and polysilanes that is highly selective and proceeds under mild conditions. New lowvalent nickel hydride complexes are used as catalysts and secondary silanes, RR′SiH2, are obtained as products in high purity.
    在Si-Si键形成下有机硅烷(R x SiH 4- x)的脱氢反应是引起广泛研究的导致低聚硅烷或聚硅烷的过程。对逆反应的研究很少。迄今为止,Si-Si键的氢解需要非常苛刻的条件,并且非常无选择性,导致产生多种副产物。在这里,我们描述了一种新的低聚硅烷和聚硅烷的催化加氢方法,该方法具有很高的选择性,并在温和的条件下进行。新型低价氢化配合物用作催化剂,仲硅烷RR'SiH 2作为高纯度产品获得。
  • (Me<sub>3</sub>N)Mo(CO)<sub>5</sub>-Catalyzed Reduction of DMF by Disiloxane and Disilane Moieties: Fate of the Silicon-Containing Fragments
    作者:Hemant K. Sharma、Renzo Arias-Ugarte、David Tomlinson、Rie Gappa、Alejandro J. Metta-Magaña、Haruhiko Ito、Keith H. Pannell
    DOI:10.1021/om301206c
    日期:2013.7.22
    hydrodisilanes, R3SiSiMe2H (2; R = alkyl, aryl), as reductants for N,N-dimethylformamide (DMF) in the presence of (Me3N)Mo(CO)5 as a catalyst led to the formation of a series of novel and structurally interesting siloxanes as well as trimethylamine. In the case of 1 the cyclic poly(dimethylsiloxanes) D4 and D6 are obtained, and for 2 the products are bis(disilyl) ethers, (R3SiSiMe2)2O. Siloxymethylamine
    在(Me 3 N)存在下,使用HSiMe 2 OSiMe 2 H(1)和各种氢化乙硅烷R 3 SiSiMe 2 H(2 ; R =烷基,芳基)作为N,N-二甲基甲酰胺(DMF)的还原剂Mo(CO)5作为催化剂导致形成了一系列新颖的和结构上令人感兴趣的硅氧烷以及三甲胺。在1的情况下,获得环状聚(二甲基硅氧烷)D 4和D 6,而对于2的产物是双(二甲硅烷基)醚,(R 3 SiSiMe 2)2个从DMF的初始氢化硅烷化所得O. Siloxymethylamine中间体,(ME 2 NCH 2 OSiMe 2)2 O(3)和R 3 SiSiMe 2 OCH 2 NME 2(4 ; R = Me中,PH),从反应1和2,可以分别观察到,在的情况下3,分离和纯化。在各自的起始硅烷和催化剂的存在下,中间体容易反应形成合适的硅氧烷材料和三甲胺。通过与R反应将化合物3官能化3 ECl(E = Si,Ge,R
  • 一种大环二甲基硅氧烷化合物的制备方法
    申请人:壮铭新材料科技江苏有限公司
    公开号:CN107200751B
    公开(公告)日:2020-04-07
    本发明公开了一种高效的大环二甲基硅氧烷化合物的制备方法,包括以下步骤:(1)以含氢双封头和八甲基环四硅氧烷为原料,在氢氧化钠或者氢氧化钾溶液中开环,再插入,可以得到二甲基氢封端的直连硅氧烷;(2)将二甲基氢封端的直连硅氧烷三氯化铝催化作用下,跟乙酰氯化,得到而甲基氯硅烷封端的直连硅氧烷;(3)将直连硅氧烷在碱性条件下解可以得到各种大环的二甲基环体。该制备方法步骤简单,经济和安全的工艺,由简单的原料出发,能够获得高纯度的各种大环二甲基基环体产品,从而避免了高难度的精馏,而且非常适应工业化生产。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
hnmr
mass
cnmr
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(2-溴乙氧基)-特丁基二甲基硅烷 鲸蜡基聚二甲基硅氧烷 骨化醇杂质DCP 马沙骨化醇中间体 马来酸双(三甲硅烷)酯 顺式-二氯二(二甲基硒醚)铂(II) 顺-N-(1-(2-乙氧基乙基)-3-甲基-4-哌啶基)-N-苯基苯酰胺 降钙素杂质13 降冰片烯基乙基三甲氧基硅烷 降冰片烯基乙基-POSS 间-氨基苯基三甲氧基硅烷 镓,二(1,1-二甲基乙基)甲基- 镁,氯[[二甲基(1-甲基乙氧基)甲硅烷基]甲基]- 锑,二溴三丁基- 铷,[三(三甲基甲硅烷基)甲基]- 铂(0)-1,3-二乙烯-1,1,3,3-四甲基二硅氧烷 钾(4-{[二甲基(2-甲基-2-丙基)硅烷基]氧基}-1-丁炔-1-基)(三氟)硼酸酯(1-) 金刚烷基乙基三氯硅烷 酰氧基丙基双封头 达格列净杂质 辛醛,8-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧代]- 辛甲基-1,4-二氧杂-2,3,5,6-四硅杂环己烷 辛基铵甲烷砷酸盐 辛基衍生化硅胶(C8)ZORBAX?LP100/40C8 辛基硅三醇 辛基甲基二乙氧基硅烷 辛基三甲氧基硅烷 辛基三氯硅烷 辛基(三苯基)硅烷 辛乙基三硅氧烷 路易氏剂-3 路易氏剂-2 路易士剂 试剂Cyanomethyl[3-(trimethoxysilyl)propyl]trithiocarbonate 试剂3-[Tris(trimethylsiloxy)silyl]propylvinylcarbamate 试剂3-(Trimethoxysilyl)propylvinylcarbamate 试剂2-(Trimethylsilyl)cyclopent-2-en-1-one 试剂11-Azidoundecyltriethoxysilane 西甲硅油杂质14 衣康酸二(三甲基硅基)酯 苯胺,4-[2-(三乙氧基甲硅烷基)乙基]- 苯磺酸,羟基-,盐,单钠聚合甲醛,1,3,5-三嗪-2,4,6-三胺和脲 苯甲醇,a-[(三苯代甲硅烷基)甲基]- 苯并磷杂硅杂英,5,10-二氢-10,10-二甲基-5-苯基- 苯基二甲基氯硅烷 苯基二甲基乙氧基硅 苯基二甲基(2'-甲氧基乙氧基)硅烷 苯基乙酰氧基三甲基硅烷 苯基三辛基硅烷 苯基三甲氧基硅烷